These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 18327813

  • 1. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Herrington JD, Jaskiewicz AD, Song J.
    Cancer; 2008 May 01; 112(9):2080-7. PubMed ID: 18327813
    [Abstract] [Full Text] [Related]

  • 2. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.
    Cancer; 2003 May 01; 97(9):2290-300. PubMed ID: 12712486
    [Abstract] [Full Text] [Related]

  • 3. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 15; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 5. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.
    Eur J Cancer; 2005 Jun 15; 41(9):1278-85. PubMed ID: 15939263
    [Abstract] [Full Text] [Related]

  • 6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.
    Breast Cancer Res Treat; 2009 Feb 15; 113(3):529-35. PubMed ID: 18327706
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan 15; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 9. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug 15; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Aug 15; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 11. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
    Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B, Adolescent Aprepitant in Cancer Study Group.
    Pediatr Blood Cancer; 2009 Feb 15; 52(2):242-7. PubMed ID: 18985740
    [Abstract] [Full Text] [Related]

  • 12. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F.
    Ann Oncol; 2015 Jun 15; 26(6):1248-1253. PubMed ID: 25743855
    [Abstract] [Full Text] [Related]

  • 13. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct 15; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 14. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

  • 15. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG, Berglind AM, Andersson H, Boman K, Högberg T, Hallgren M, Schmidt M.
    Cancer; 1998 Sep 01; 83(5):1022-32. PubMed ID: 9731907
    [Abstract] [Full Text] [Related]

  • 16. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 17. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 01; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 18. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
    Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P.
    Transplant Proc; 2011 Oct 01; 43(8):3107-10. PubMed ID: 21996238
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L, Denaro A, Agustoni F, Bajetta E.
    J Support Oncol; 2012 Oct 01; 10(2):65-71. PubMed ID: 22005217
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.
    Support Care Cancer; 2009 May 01; 17(5):589-94. PubMed ID: 19037667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.